Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic EGFR CLIA Test

Transgenomic has launched its new CLIA laboratory-based test for EGFR mutation detection in cancer patients using proprietary MX-ICP technology with any sample type.

The test is for EGFR exon 20 T790M mutations that affect the utility of tyrosine kinase inhibitor drugs for non-small cell lung cancer and EGFR exon 12 S492R mutations that signify resistance to the widely-prescribed drug cetuximab in coloretal cancer patients. 

The test can use tissue, plasma, fine needle aspiration, bronchoscopy, cytology, and other bodily fluid samples. Actionable results will be available in seven to 10 working days, Transgenomic said.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.